ACAD ACADIA Pharmaceuticals
ACADIA Pharmaceuticals earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 4 Nov | EPS | 0.21 | — | — |
| Rev | $332.6M | — | — |
Insider trades
Open-market buys and sales by ACAD's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $785K sold by 2 insiders outside a trading plan
- $885K sold by 2 insiders under 10b5-1 plans
-
Mark C. Schneyer CFOPlanned sale$587K 20,141 shares at $29.16 23% of stakeTraded Aug 5–6 Filed Aug 7
-
James Kihara Principal Accounting OfficerPlanned sale$298K 11,421 shares at $26.08 47% of stakeTraded Jun 26 Filed Jun 29
-
James Kihara Principal Accounting OfficerSale$114K 5,401 shares at $21.18 18% of stakeTraded May 26 Filed May 27
-
James M Daly DirectorSale$671K 30,000 shares at $22.37 88% of stakeTraded Nov 10, 2025 Filed Nov 12, 2025
Also filed in the last 12 months, not counted as buying or selling: 25 option exercises, 19 sales to cover taxes, and 3 stock grants.
SEC filings
Recent issuer filings from EDGAR, 13 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.